DarioHealth Corp. (DRIO) Stock Forecast
DRIO analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.60 / 5 from 5 analysts
- Price target
- $13.60 average of analyst targets
- Upside to target
- +182.2% from the latest close
- Next earnings
- November 12, 2026 EPS estimate $-0.68
- 52-week range
- $4.82 – $16.19
DRIO analyst ratings
5 analystsNumber of analysts at each rating.
DRIO price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
DRIO earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.51 | −$0.51 | −$0.51 | −$2.22 | +77.0% | 2 |
| Current fiscal year (2026) | −$2.46 | −$2.48 | −$2.45 | −$7.33 | +66.4% | 2 |
| Next fiscal year (2027) | −$1.12 | −$1.46 | −$0.78 | −$2.46 | +54.6% | 2 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
DRIO revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $5.2M | $5.2M | $5.3M | +4.7% | 3 |
| Current fiscal year (2026) | $21.9M | $21.6M | $22.4M | −2.1% | 4 |
| Next fiscal year (2027) | $30.4M | $26.1M | $40.0M | +38.8% | 5 |
DRIO EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
DRIO revenue: reported and forecast
DRIO EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.59 | −$0.62 | −$0.62 | −$0.62 | −$0.51 | −13.6% | 1 up · 0 down |
| Current fiscal year (2026) | −$2.57 | −$2.81 | −$2.81 | −$2.81 | −$2.46 | −4.1% | 1 up · 0 down |
| Next fiscal year (2027) | −$0.66 | −$0.68 | −$0.68 | −$0.68 | −$1.12 | +69.7% | 0 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
DRIO earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; DRIO beat in 7 of 12.
What analysts expect from DRIO
5 analysts cover DarioHealth; their consensus rating is strong buy (4.60 on a 1–5 scale, where 5 is a strong buy). The average price target is $13.60, 182.2% above the latest close of $4.82. Analysts expect earnings of −$2.46 per share for 2026, +66.4% from a year earlier. For 2027 the average estimate is −$1.12 per share on revenue of $30.4 million. DarioHealth beat the EPS estimate in 7 of the last 12 quarters.
Related: DRIO income statement, DRIO key metrics, DRIO chart. See the DRIO stock overview for the latest quote and news.
DRIO forecast FAQ
What is DarioHealth's price target?
The average analyst price target for DarioHealth is $13.60, 182.2% above the latest close of $4.82.
Is DarioHealth a buy, hold or sell?
Of 5 analysts covering DarioHealth, 4 rate it a strong buy, 0 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is DarioHealth's EPS forecast?
Analysts forecast −$2.46 per share for 2026 (range −$2.48 to −$2.45); for 2027 the estimate is −$1.12.
What is DarioHealth's revenue forecast?
The average revenue estimate for 2026 is $21.9 million, growth of −2.1%; for 2027 it is $30.4 million.
When does DarioHealth report earnings?
DarioHealth is expected to report results for the quarter ending September 30, 2026 on November 12, 2026 before the market opens; the EPS estimate is $-0.68.
Does DarioHealth usually beat earnings estimates?
DarioHealth reported EPS at or above the analyst estimate in 7 of the last 12 quarters.